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Diabetes mellitus is a major risk factor for cardiovascular
diseases.1 Microvascular complications i.e. retinopathy,
nephropathy and neuropathy result in increased
morbidity in patients with diabetes mellitus.2
Clopidogrel is a prodrug that is absorbed from the
intestine and metabolised by oxidative pathways of
hepatic cytochrome P450 enzymes i.e. CYP2C19,
CYP3A4/5, CYP2B6, CYP2C9 and CYP1A2.3 These
enzymes oxidize clopidogrel to 2-oxo-clopidogrel which
is further metabolised to an active thiol compound. This
short lived active metabolite binds with platelet P2Y12
receptors through disulfide bonds between the reactive
thiol group and the two cysteine residues (cys17 and
cys270) of extracellular domains of P2Y12 receptor.
Binding of clopidogrel to the P2Y12 receptors is selective
and irreversible.4 Because of the irreversible binding,
effect of clopidogrel persists for the lifespan of the
affected platelets.
This study was undertaken with the primary object of
determining platelet reactivity in patients with untreated
type 2 diabetes mellitus and to study the effect of
clopidogrel administration on the state of in vivo platelet
activation in these patients. It was extended to include
the effect of clopidogrel on reactive platelet CD markers
after in vitro pre-treatment with platelet agonists. It was
postulated that platelets in patients with type 2 diabetes
mellitus circulate in the blood in hyperactive state and
predispose to thrombotic complications so frequently
encountered in these patients.
A total of 107, i.e. 32 normal individuals and 75 patients
with untreated type 2 diabetes mellitus were enrolled in
this study. Criteria for normal individuals were; healthy
individuals with no history of any illness during the past
6 weeks, no history of drug intake particularly anti-
platelet agent and no history of smoking. Normal
individuals were selected from the hospital and
laboratory staff. Inclusion criteria for patients were
untreated type 2 diabetes mellitus with no history of drug
intake particularly the anti-diabetic or anti-platelet drug,
no evidence of diabetic complications and non-smokers.
Diabetic patients with a history of drug intake for
diabetes, with cardiovascular diseases, macro or micro
vascular complications or smokers were excluded from
the study.
Patients with untreated type 2 diabetes mellitus were
selected from Baqai Institute of Diabetes and
Endocrinology (BIDE) and Baqai University Hospital,
Nazimabad. Informed written consent was taken from all
subjects. This study was conducted from March 2010 to
July 2012 and was approved by the ethics committee of
Baqai Medical University, Karachi.
This study was carried out in two steps. In the first step
normal as well as diabetic patients were selected and
tested for various laboratory parameters and platelets
flow cytometry. Initially 120 individuals were enrolled in
the study of which 13 individuals were excluded due to
non-compliance (n=10) and abnormal laboratory
findings in 'normal' subjects (n=3). A total of 107
individuals i.e. 32 normal subjects (male 15, female 17)
and 75 (male 28, female 47) patients with type 2
diabetes mellitus were enrolled in the study. Mean age
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of the normal subjects was 51 ± 12 years while that of
the diabetic group was 56 ± 16 years.
Blood samples were collected from the antecubital vein
under minimal tourniquet pressure to avoid spontaneous
activation of platelets. Blood was collected in
vacutainers (BD Biosciences). Three ml of blood was
collected in EDTA tubes for CBC and HbA1C, 2.7 ml of
blood was added to sodium citrate tube for platelet flow
cytometry while 5 ml of blood was collected in gel tube
for biochemical studies.
Complete blood counts of all samples were determined
using automated cell analyzer. HbA1C was determined
using micro lab 200. Fasting and random blood sugar,
urea, creatinine, cholesterol, triglycerides, high density
and low density lipoproteins were determined using
automated biochemistry analyzer (Hitachi 902 Roche).
The citrated blood sample was analyzed for percentage
fluorescence positive platelets for anti-CD41, 61, 62p
and 63 by FACS Calibur (BD Biosciences). Forward light
Scatter (FS) and Side light Scatter (SS) were displayed
on logarithmic scales. Platelets were identified by
binding with FITC (fluorescein isothiocyanate) and
PE (phycoerythrin) labeled anti-CD42 and anti-CD61
antibodies. Antibodies labeled platelets were analyzed
for 10,000 platelet events using flow cytometer. Results
were expressed as mean fluorescence percentage of
positive platelets.
After collection of the first blood sample, clopidogrel was
administrated to each individual (75 mg/day) for 10 days
in the second step of the study. Second blood samples
were collected after the administration of clopidogrel for
flow cytometry. Samples were analyzed according to
the same procedure. Data were analyzed using the
Statistical Package for Social Sciences (SPSS) version
16.0. Paired t-test was used for the comparison of
parameters. A p-value of < 0.05 was considered
statistically significant.
Platelets flow cytometry is a simple and reliable test for
the evaluation of therapeutic efficacy of anti-platelet
drugs. Compared with normal subjects, resting platelets
in diabetic patients after clopidogrel administration show
increased expression of CD63 (p < 0.001) as illustrated
in Table I. Similarly, CD62p showed increased positivity
(p < 0.001) in diabetic patients as compared with normal
individuals. CD41 and CD61 activity, however, did not
show any significant difference between normal
individuals and patients with diabetes as shown in
Table I. Activation of platelets, using ADP as agonist, in
normal subjects and in patients with diabetes did not
show any difference in the positivity of CD41 and CD61
after clopidogrel administration as shown in Table II. This
observation suggests that CD41 and CD61 are the
platelet markers not affected by clopidogrel after
activation with ADP and their expression remains
unchanged. Platelets of normal subjects had decreased
CD63 and CD62p percentage fluorescent positivity after
clopidogrel administration as compared with diabetic
patients as shown in Table II. These findings suggest
that ADP activated platelets in diabetic patients have
increased reactivity even after the administration of anti-
platelet drug. Patients with untreated type 2 diabetes
showed low response to clopidogrel. CD63 and CD62p
expression after stimulation with ADP identify clopidogrel
non-responsiveness; this correlates well with increased
expression of these receptors.5
This study provides an avenue to assess the effect of
varying doses of clopidogrel on suppressing platelet
activation. In patients with persistent thrombotic
complications despite continued administration of
clopidogrel may be benefitted if an effective dose is
administered which may be determined by titrating the
dose and offering a customized dose of clopidogrel as
prophylactic antithrombotic therapy.
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Table I: Comparison of platelet CD markers at resting state in normal
individuals and in patients with diabetes mellitus.
Variables Normal Diabetics
(n=32) (n=75)
CD 41
Pre-treatment 89.06 ± 4.06 89.95 ± 4.89
Post-treatment 90.27 ± 3.97 89.80 ± 4.06
p-value 0.09 0.880
CD61
Pre-treatment 90.13 ± 4.45 90.53 ± 5.04
Post-treatment 90.03 ± 4.55 90.85 ± 4.39
p-value 0.925 0.774
CD63
Pre-treatment 33.31 ± 5.93 38.27 ± 5.17
Post-treatment 13.79 ± 6.24 12.59 ± 4.11
p-value < 0.001 < 0.001
CD62p
Pre-treatment 29.17 ± 4.87 33. 78 ± 4.39
Post-treatment 10.68 ± 5.82 12.59 ± 4.11
p-value < 0.001 < 0.001
Paired t-test was used for comparison.
Table II: Comparison of platelets CD markers after activation of platelets
with ADP in normal subjects and in diabetics.
variables Normal (n=32) Diabetics (n=75)
CD 41
Pre-treatment 89.65 ± 5.58 89.27 ± 4.62
Post-treatment 90.37 ± 4.20 91.87 ± 4.23
p-value 0.613 0.07
CD61
Pre-treatment 91.44 ± 4.92 89.65 ± 4.72
Post-treatment 90.00 ± 4.45 90.25 ± 4.65
p-value 0.290 0.525
CD63
Pre-treatment 84.89 ± 5.50 85.48 ± 5.69
Post-treatment 25.34 ± 8.32 20.14 ± 3.71
p-value < 0.001 < 0.001
CD62p
Pre-treatment 83.68 ± 5.37 83.72 ± 5.09
Post-treatment 22.65 ± 5.47 16.70 ± 3.24
p-value < 0.001 < 0.001
Paired t-test was used for comparison.
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P2Y12 receptors are up-regulated in patients with
diabetes mellitus.6 This leads to decreased response to
clopidogrel in patients with diabetes mellitus as
compared to non-diabetics.6 Antiplatelet effect of
clopidogrel varies among patients with diabetes. Those
with enhanced platelet reactivity are at increased risk of
atherothrombosis.7 Accelerated procoagulant activities
has been associated with an increased risk of ischemic
events and may explain as to why these events occur
despite pharmacological blockade of specific platelet
targets.8
It has been observed that clopidogrel pharmacodynamic
response varies significantly. Based upon their
response, patients are classified as responders, low
responders, poor responders, non-responders or
clopidogrel-resistant.9 Sub-optimal clopidogrel response
is seen in some patients with diabetes mellitus.7
Mechanism of impaired clopidogrel response in these
patients is unclear. Several hypotheses have been
put forward to explain variations in response to
clopidogrel. Decreased circulating active metabolites of
clopidogrel, genetic differences in P2Y12 receptors,
increased expression of P2Y12 receptors, increased
circulating ADP and upregulation of other platelet
activation pathways, poor glycemic control, and non-
compliance are some of the causes of clopidogrel non-
responsiveness.
In the light of the above results and discussion it is
concluded that; CD41 and CD61 do not show any
change after treatment with ADP and after the
administration of clopidogrel. CD63 and CD62p positivity
in normal resting and ADP stimulated platelets
decreases significantly after clopidogrel treatment.
CD63 and CD62p positivity in resting and ADP
stimulated platelets in the patients also decreases after
clopidogrel treatment. CD63 and CD62p positivity in
resting platelets in the patients does not decrease as
much as in normal subjects after clopidogrel treatment.
It is, however, lower than before clopidogrel treatment in
both groups.
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